申请人:ASTRAZENECA UK LTD
公开号:WO2000058305A1
公开(公告)日:2000-10-05
The invention provides compounds of general formula (I) wherein: R1 represents optionally substituted C¿1?-C12 alkyl or optionally substituted 3- to 10-membered saturated or unsaturated ring system comprising up to two ring carbon atoms that form carbonyl groups and comprising up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulfur; m is 0-1; Q represents OCH2, C1-C4 alkylene or C2-C4 alkenylene; T represents C(O)NH, or when m is 0, T may additionally represent a bond or NH, or when m is 1 and Q represents C1-C4 alkylene, T may additionally represent NH; n is 1-4; each R?2 and R3¿ independently represents H or C¿1?-C4 alkyl; V represents N, and W represents N or CH; X represents O, C(O), CH(OH), SO2, NH or N(C1-C6 alkyl), provided that when W represents N, then X represents either C(O) or SO2 and when W represents CH, then X is other than SO2; R?4¿ represents optionally substituted phenyl; R?5 and R6¿ each independently represent H, C¿1?-C6 alkyl or hydroxyC1-C6 alkyl, or R?5 and R6¿ together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring; R?7 and R8¿ each independently represent H or C¿1?-C6 alkyl; and R?9¿ represents OH or -NR7R8; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.